These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 615720)

  • 1. Renal clearance of pyridostigmine in patients with myasthenia gravis.
    Chan K; Calvey TN
    Eur Neurol; 1977; 16(1-6):69-72. PubMed ID: 615720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of chronic pyridostigmine administration on pyridostigmine-14C metabolism in myasthenia gravis.
    Kornfeld P; Wolf RL; Samuels AJ; Osserman KE
    Neurology; 1971 May; 21(5):550-2. PubMed ID: 5104099
    [No Abstract]   [Full Text] [Related]  

  • 3. Renal clearance of pyridostigmine in myasthenic patients and volunteers under the influence of ranitidine and pirenzepine.
    Eiermann B; Sommer N; Winne D; Schumm F; Maier U; Breyer-Pfaff U
    Xenobiotica; 1993 Nov; 23(11):1263-75. PubMed ID: 8310710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyridostigmine metabolism in man.
    Somani SM; Roberts JB; Wilson A
    Clin Pharmacol Ther; 1972; 13(3):393-9. PubMed ID: 4554662
    [No Abstract]   [Full Text] [Related]  

  • 5. Malabsorption of pyridostigmine in patients with myasthenia gravis.
    Cohan SL; Dretchen KL; Neal A
    Neurology; 1977 Mar; 27(3):299-301. PubMed ID: 557769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of neostigmine on pyridostigmine bioavailability in myasthenic patients after oral administration.
    Chan K; Davison SC; Dehghan A; Hyman N
    Methods Find Exp Clin Pharmacol; 1981; 3(5):291-6. PubMed ID: 7329157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism of 14C-labeled pyridostigmine in myasthenia gravis. Evidence for multiple metabolites.
    Kornfeld P; Samuels AJ; Wolf RL; Osserman KE
    Neurology; 1970 Jul; 20(7):634-41. PubMed ID: 5463535
    [No Abstract]   [Full Text] [Related]  

  • 8. Studies in myasthenia gravis. Pyridostigmine-C14 metabolism after thymectomy.
    Kornfeld P; Mittag TN; Genkins G; Horowitz S; Papatestas AE
    Neurology; 1975 Oct; 25(10):998-9. PubMed ID: 1237111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis.
    Breyer-Pfaff U; Maier U; Brinkmann AM; Schumm F
    Clin Pharmacol Ther; 1985 May; 37(5):495-501. PubMed ID: 3987173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steady state kinetics of pyridostigmine in myasthenia gravis.
    Sørensen PS; Flachs H; Friis ML; Hvidberg EF; Paulson OB
    Neurology; 1984 Aug; 34(8):1020-4. PubMed ID: 6540381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma pyridostigmine levels in myasthenia gravis.
    White MC; De Silva P; Havard CW
    Neurology; 1981 Feb; 31(2):145-50. PubMed ID: 7193298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma pyridostigmine levels in patients with myasthenia gravis.
    Calvey TN; Chan K
    Clin Pharmacol Ther; 1977 Feb; 21(2):187-93. PubMed ID: 837637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with insensitivity to pyridostigmine therapy in Thai patients with ocular myasthenia gravis.
    Chirapapaisan N; Tanormrod S; Chuenkongkaew W
    Asian Pac J Allergy Immunol; 2007 Mar; 25(1):13-6. PubMed ID: 17891917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of use of pyridostigmine and requirement of vecuronium in patients with myasthenia gravis.
    Tripathi M; Kaushik S; Dubey P
    J Postgrad Med; 2003; 49(4):311-4; discussion 314-5. PubMed ID: 14699228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Celebrating the 70 years of pyridostigmine on therapy of Myasthenia Gravis: historical aspects of the preliminary trials.
    Lorenzoni PJ; Kay CSK; Ducci RD; Fustes OJH; Werneck LC; Scola RH
    Arq Neuropsiquiatr; 2020 Mar; 78(3):179-181. PubMed ID: 32215460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma concentration of pyridostigmine and effects in myastenia gravis.
    Chan K; Calvey TN
    Clin Pharmacol Ther; 1977 Nov; 22(5 Pt 1):596-601. PubMed ID: 199393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Plasmapheresis in myasthenia gravis].
    Jauregui WO; Di Gressia C; Herrera ME; Muchnik S
    Medicina (B Aires); 1981; 41(5):511-9. PubMed ID: 7345333
    [No Abstract]   [Full Text] [Related]  

  • 18. Quantitative correlation between plasma pyridostigmine levels and neuromuscular function in myasthenia gravis.
    Milner-Brown HS; Mellenthin M; Sharma ML; Miller RG
    Neurology; 1987 May; 37(5):800-3. PubMed ID: 3574680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescription profile of pyridostigmine use in a population of patients with myasthenia gravis.
    Machado-Alba JE; Calvo-Torres LF; Gaviria-Mendoza A; Augusto MejíA-Vélez C
    Muscle Nerve; 2017 Dec; 56(6):1041-1046. PubMed ID: 28214292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of erythrocyte-bound acetylcholinesterase activity for monitoring pyridostigmine therapy in myasthenia gravis.
    Henze T; Nenner M; Michaelis HC
    J Neurol; 1991 Jul; 238(4):225-9. PubMed ID: 1895153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.